DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments.
Vous n'êtes pas connecté
Danaher (DHR) benefits from strength in the clinical diagnostics business, Abcam buyout and pro-investor policies. However, softness in its Instrument unit is concerning.
DHR's third-quarter earnings and sales surpass estimates, benefiting from the solid performance of its Life Sciences and Diagnostics segments.
ITW's third-quarter results are likely to gain from strength across the Automotive OEM and Specialty Products units. Softness in the Welding segment...
The recent meeting of BRICS (comprising Russia, Brazil, China, India, and South Africa) in Kazan in October 2024 has significant implications for...
The energy industry is experiencing a sharp increase in supply chain risks, largely driven by its growing reliance on external vendors. According...
Not specified: headcount AG: Clinical Development Lead Description Join a cutting-edge, clinical-stage Swiss biotech company, recognized...
Not specified: headcount AG: Clinical Development Lead Description Join a cutting-edge, clinical-stage Swiss biotech company, recognized...
Nqobile Bhebhe, nqobile.bhebhe@chronicle.co.zw ZIMBABWE’S pro-business policies continue to boost investor confidence attracting over US$1 billion...
The Department of Health Research (DHR) under the ministry of health & family welfare, Government of India, is calling for applications from Indian...
By Nivedita Raju and Sarah Erickson In February 2024, United States government officialsclaimedto haveintelligencethat Russia was developing...
Prior to the Russian Revolution in 1917, Russian cities had ethnic quarters, or ghettos, where members of some minorities lived to maintain their...